Total Payments
$1,588
2023 Payments
$45.82
Companies
24
Transactions
43
Medicare Patients
4,550
Medicare Billing
$648,150
Payment Breakdown by Category
Food & Beverage$1,388 (87.4%)
Education$199.92 (12.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,388 | 40 | 87.4% |
| Education | $199.92 | 3 | 12.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $417.81 | 7 | $0 (2019) |
| Daiichi Sankyo Inc. | $150.65 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $141.02 | 3 | $0 (2022) |
| Advanced Accelerator Applications | $120.24 | 1 | $0 (2019) |
| Seagen Inc. | $120.23 | 1 | $0 (2022) |
| Agios Pharmaceuticals, Inc. | $94.96 | 1 | $0 (2018) |
| Eisai Inc. | $77.34 | 1 | $0 (2017) |
| PFIZER INC. | $56.27 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $50.70 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $44.50 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $45.82 | 2 | Pharmacyclics LLC, An AbbVie Company ($25.47) |
| 2022 | $254.06 | 3 | Seagen Inc. ($120.23) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $150.65 | 1 | Daiichi Sankyo Inc. ($150.65) |
| 2019 | $473.05 | 23 | Advanced Accelerator Applications ($120.24) |
| 2018 | $472.11 | 10 | Amgen Inc. ($304.43) |
| 2017 | $180.10 | 3 | Amgen Inc. ($89.00) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/13/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Oncology | ||||||
| 08/16/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $120.23 | General |
| Category: Oncology | ||||||
| 06/01/2022 | Pacira Pharmaceuticals Incorporated | Exparel (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Pain Management | ||||||
| 04/27/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $114.00 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/05/2020 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $150.65 | General |
| Category: Oncology | ||||||
| 11/15/2019 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $12.39 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2019 | Advanced Accelerator Applications | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $120.24 | General |
| Category: Radioactive targeted therapy - Neuroendocrine tumors | ||||||
| 09/04/2019 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2019 | Amgen Inc. | Neulasta (Biological), Nplate, Vectibix | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: Oncology | ||||||
| 06/10/2019 | GENZYME CORPORATION | CERDELGA (Drug), GAUCHER-DISEASE | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: RARE DISEASE GENETICS | ||||||
| 05/09/2019 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2019 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $11.33 | General |
| Category: Oncology | ||||||
| 04/25/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2019 | Amgen Inc. | Neulasta (Biological), XGEVA | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: Oncology | ||||||
| 03/04/2019 | Sun Pharmaceutical Industries Inc. | ODOMZO (Drug), YONSA | Food and Beverage | Cash or cash equivalent | $39.23 | General |
| Category: Oncology | ||||||
| 02/26/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
| 02/18/2019 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2019 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), KISQALI | Food and Beverage | In-kind items and services | $10.96 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2019 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Oncology | ||||||
| 01/23/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,168 | 2,006 | $544,595 | $144,943 |
| 2022 | 12 | 1,145 | 1,844 | $529,312 | $132,262 |
| 2021 | 13 | 1,309 | 2,188 | $641,915 | $167,005 |
| 2020 | 12 | 928 | 2,011 | $699,438 | $203,940 |
Total Patients
4,550
Total Services
8,049
Medicare Billing
$648,150
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 394 | 691 | $193,480 | $46,265 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 106 | 313 | $128,643 | $34,006 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 385 | 475 | $89,913 | $20,575 | 22.9% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 47 | 194 | $13,580 | $13,426 | 98.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 74 | 74 | $38,406 | $9,631 | 25.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 135 | $30,645 | $8,125 | 26.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 34 | $16,932 | $4,554 | 26.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $14,134 | $3,349 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 30 | $10,260 | $2,757 | 26.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $8,602 | $2,254 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 290 | 651 | $189,765 | $46,184 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 426 | 595 | $117,946 | $26,607 | 22.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 59 | 91 | $43,680 | $14,506 | 33.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 98 | 98 | $53,360 | $12,802 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 77 | $32,323 | $8,337 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $22,061 | $5,287 | 24.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 97 | $19,739 | $5,250 | 26.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 53 | $15,476 | $4,338 | 28.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 41 | 41 | $15,854 | $4,120 | 26.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 21 | $11,952 | $2,964 | 24.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 25 | 41 | $4,513 | $1,236 | 27.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 22 | 24 | $2,643 | $631.82 | 23.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 313 | 777 | $225,519 | $54,906 | 24.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 108 | 205 | $98,400 | $32,800 | 33.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 412 | 577 | $114,618 | $27,987 | 24.4% |
About Dr. Stephanie Lindauer, MD
Dr. Stephanie Lindauer, MD is a Hematology & Oncology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2011. The National Provider Identifier (NPI) number assigned to this provider is 1902199813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephanie Lindauer, MD has received a total of $1,588 in payments from pharmaceutical and medical device companies, with $45.82 received in 2023. These payments were reported across 43 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,388).
As a Medicare-enrolled provider, Lindauer has provided services to 4,550 Medicare beneficiaries, totaling 8,049 services with total Medicare billing of $648,150. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Scottsdale, AZ
- Active Since 05/25/2011
- Last Updated 10/17/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1902199813
Products in Payments
- Enhertu (Drug) $150.65
- XGEVA (Biological) $125.00
- LUTATHERA (Drug) $120.24
- TUKYSA (Drug) $120.23
- TIBSOVO (Drug) $94.96
- Halaven (Drug) $77.34
- Kyprolis (Biological) $67.78
- KEYTRUDA (Biological) $44.50
- XTANDI (Drug) $40.99
- ODOMZO (Drug) $39.23
- Neulasta (Biological) $37.03
- GILOTRIF (Drug) $29.60
- EPKINLY (Drug) $25.47
- AFINITOR (Drug) $24.26
- NINLARO (Drug) $23.44
- CYRAMZA (Drug) $20.83
- ALIMTA (Drug) $20.75
- Tibsovo (Drug) $20.35
- Exparel (Drug) $19.83
- CERDELGA (Drug) $18.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Scottsdale
Jeffrey Schriber, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Tanios Bekaii-Saab, M.d, M.D
Hematology & Oncology — Payments: $675,364
Hematology & Oncology $675,364
Dr. Rajesh Kukunoor, M.d, M.D
Hematology & Oncology — Payments: $515,496
Hematology & Oncology $515,496
Dr. Alexander Stewart, M.d, M.D
Hematology & Oncology — Payments: $291,151
Hematology & Oncology $291,151
Dr. Daniel Von Hoff, M.d, M.D
Hematology & Oncology — Payments: $248,837
Hematology & Oncology $248,837
Alan Bryce, M.d, M.D
Hematology & Oncology — Payments: $151,308
Hematology & Oncology $151,308